Bharat Parenterals Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Bharat Parenterals Ltd filed with BSE on 20 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Bharat Parenterals reported consolidated FY26 revenue of INR345.4 crores, roughly flat year-on-year, with consolidated EBITDA rising to INR15.8 crores from INR2.7 crores, driven mainly by a narrowing of losses at subsidiary Innoxel Lifesciences. Standalone BPL revenue declined about 23% due to deferred export tenders, exit from low-margin business, and production line upgrades, while Varenyam Healthcare turned profitable with 13.7% revenue growth and Innoxel grew revenue 174.1% on licensing and milestone income. Management issued FY27 guidance across its three operating businesses and described FY26 as a transition year ahead of an expected commercial inflection.
Numbers mentioned
Consolidated revenue: INR345.4 crores (FY26)
p. 3
“our consolidated revenue for FY '26 stood at INR345.4 crores compared to INR340 crores last year”
Bhahim Desai, page 3 of the filed PDF · View the filing
Consolidated EBITDA: INR 15.8 crores (FY26)
p. 4
“Consolidated EBITDA for FY '26 was INR 15.8 crores against INR 2.7 crores last year.”
Bhahim Desai, page 4 of the filed PDF · View the filing
Consolidated PAT: INR 27.3 crores (FY26)
p. 4
“our consolidated PAT narrowed to INR 27.3 crores from INR 43.7 crores, an improvement of about INR 16 crores at the bottom”
Bhahim Desai, page 4 of the filed PDF · View the filing
BPL standalone revenue: INR234 crores (FY26)
p. 4
“the revenue for FY '26 stood at INR234 crores against INR 304 crores last year, a decline of about 23%”
Bhahim Desai, page 4 of the filed PDF · View the filing
BPL standalone EBITDA margin: 9% (FY26)
p. 4
“we delivered EBITDA of INR 21 crores at a 9% margin and a PAT of INR 16 crores at a 6.8% margin”
Bhahim Desai, page 4 of the filed PDF · View the filing
Innoxel revenue: INR 72.4 crores (FY26)
p. 4
“Revenue grew to INR 72.4 crores from INR 26.4 crores last year, a growth of 174%”
Bhahim Desai, page 4 of the filed PDF · View the filing
Innoxel EBITDA loss: INR 6.9 crores (FY26)
p. 5
“EBITDA loss for the year narrowed sharply to INR 6.9 crores from INR 30.4 crores last year”
Bhahim Desai, page 5 of the filed PDF · View the filing
Innoxel Q4 EBITDA: INR 1.4 crores (Q4 FY26)
p. 5
“We did INR 1.4 crores of EBITDA in the quarter against losses in every prior quarter.”
Bhahim Desai, page 5 of the filed PDF · View the filing
Varenyam Healthcare revenue: INR 58.4 crores (FY26)
p. 5
“Revenue grew from INR 51.4 crores last year to INR 58.4 crores this year, that's a growth of 13.7% year-on-year.”
Bhahim Desai, page 5 of the filed PDF · View the filing
Varenyam Healthcare EBITDA: INR 2.5 crores (FY26)
p. 5
“EBITDA for the year was INR 2.5 crores against a loss of INR 3 crores last year.”
Bhahim Desai, page 5 of the filed PDF · View the filing
Consolidated revenue: INR 99.6 crores (Q4 FY26)
p. 6
“Consolidated revenue in the quarter was INR 99.6 crores, up 52.8% over Q3.”
Bhahim Desai, page 6 of the filed PDF · View the filing
BPL standalone order book: INR 171 crores (as of FY26 year-end)
p. 4
“The order book today stands at INR 171 crores, which gives us reasonable visibility for FY '27.”
Bhahim Desai, page 4 of the filed PDF · View the filing
General injectable capacity utilization: 48% (FY26)
p. 4
“We are at 48% on the General, 21% on beta-lactam, and 24% on cephalosporins.”
Bhahim Desai, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Standalone business revenue growth — 10% to 15% · FY27
stated firmly by Bhahim Desai
p. 6
“For the standalone business, we expect revenue growth of 10% to 15% with EBITDA margins in the same 10% to 15% range.”
Bhahim Desai, page 6 of the filed PDF · View the filing
Innoxel revenue growth — 35% to 45% · FY27
stated firmly by Bhahim Desai
p. 6
“For Innoxel, we expect revenue growth of 35% to 45% with EBITDA margins of 20% to 25%.”
Bhahim Desai, page 6 of the filed PDF · View the filing
Innoxel out-licensing income — INR 70 crores to INR 90 crores · FY27
stated firmly by Bhahim Desai
p. 6
“overall out-licensing income is expected between INR 70 crores to INR 90 crores”
Bhahim Desai, page 6 of the filed PDF · View the filing
Varenyam Healthcare revenue growth — 20% to 25% · FY27
stated firmly by Bhahim Desai
p. 6
“For Varenyam Healthcare, we expect revenue growth of about 20% to 25% with EBITDA margins of 8% to 13%.”
Bhahim Desai, page 6 of the filed PDF · View the filing
VBPL commissioning — commissioning of manufacturing facility · September 2027
stated firmly by Bhahim Desai
p. 6
“The key milestones for this business are: commissioning of the facility in September of 2027, line validation of manufacturing lines by March 2028, our first regulatory filing under EUGMP expected to be Q1 of FY '29, and subsequently our first commercial supply in Q4 of FY '29.”
Bhahim Desai, page 6 of the filed PDF · View the filing
Standalone business peak revenue — INR 400 crores to INR 500 crores · around 2030
stated as an aspiration by Bhahim Desai
p. 7
“It is expected from the standalone business to deliver INR 400 crores to INR 500 crores of top line, but that is obviously, this will be sequential and there is, I would say, a 3-year to 4-year time before which we can expect those things to come.”
Bhahim Desai, page 7 of the filed PDF · View the filing
Standalone business revenue recovery — crossing FY25 revenue levels · FY28
stated conditionally by Bhahim Desai
p. 7
“we expect full recovery in the next year to come, going back to our FY '25 numbers, crossing our FY '25 numbers in FY '28”
Bhahim Desai, page 7 of the filed PDF · View the filing
Innoxel CMO product commercialization — two products commercialized · FY27
stated firmly by Bhahim Desai
p. 11
“there are two products that we expect to be commercialized this year. First is expected in Q2 and the second is expected between Q3 and Q4.”
Bhahim Desai, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management confirmed the guidance is based on this year's lower revenue base and cited two audit events expected to cause further disruption before recovery.
Answered by Bhahim Desai
Asked by Harshit Khadka: Is the 10-15% standalone growth guidance based on the reduced FY26 base of ~INR230 crores rather than the prior ~INR300 crores base?
p. 7
“We still expect a little bit of disruption due to two major audit events which would be at the standalone facilities which is, like I said, PIC/S and EU GMP.”
Bhahim Desai, page 7 of the filed PDF · View the filing
Management confirmed the timeline had been revised and attributed part of the delay to geopolitical disruption.
Answered by Bhahim Desai
Asked by Harshit Khadka: Has the Varenyam Bio commercialization timeline slipped from FY27 to Q4 FY29?
p. 8
“I would also like to point out that the current geopolitical disturbance has had an impact on the, I wouldn't say too much of an impact, but we are 3 months, at least one quarter running behind on schedule as to what we had expected earlier.”
Bhahim Desai, page 8 of the filed PDF · View the filing
Management said prior guidance had not been met for various reasons, so this year's guidance is set more conservatively to ensure it can be delivered.
Answered by Bhahim Desai
Asked by Saloni Arya: Why have guidance ranges across segments, especially Varenyam Healthcare, been lowered versus prior quarters?
p. 8
“this time around the guidances have been on the softer side and it is something that we feel is very, that we are very confident of achieving these guidances”
Bhahim Desai, page 8 of the filed PDF · View the filing
Management said the business is in rapid expansion mode this year, including starting a new division, which requires significant investment ahead of meaningful top-line contribution.
Answered by Bhahim Desai
Asked by Saloni Arya: Why is Varenyam Healthcare's margin guidance lower given expansion plans?
p. 9
“So there would be a significant investment that is going to go from the company towards expansion of the business with minimum expectations in terms of meaningful top-line numbers.”
Bhahim Desai, page 9 of the filed PDF · View the filing
Management said the order was received in early March 2026, later than the expected July, and supply has now started with most of the order to be delivered this year and some spillage next year.
Answered by Bhahim Desai
Asked by Avnish: What is the status of the $27 million tender order at BPL that was delayed?
p. 11
“We expected the order in July of last year, but unfortunately, we got the orders somewhere in March first week of 2026, which got us the, which is where the main delay happened.”
Bhahim Desai, page 11 of the filed PDF · View the filing
Risks flagged
Export tenders at the standalone business were deferred, delaying revenue recognition
p. 4
“we had a number of export tenders that got deferred into the next year”
Bhahim Desai, page 4 of the filed PDF · View the filing
Production lines were taken down for upgradation work ahead of EUGMP inspection, costing production days
p. 4
“we took down some of our production lines for upgradation work this year”
Bhahim Desai, page 4 of the filed PDF · View the filing
Upcoming PIC/S and EUGMP inspections expected to cause disruption to the standalone business
p. 7
“there would be some sort of disruption coming from these two inspections for this year”
Bhahim Desai, page 7 of the filed PDF · View the filing
Geopolitical disturbance has pushed back the Varenyam Bio timeline
p. 8
“we are 3 months, at least one quarter running behind on schedule as to what we had expected earlier”
Bhahim Desai, page 8 of the filed PDF · View the filing
Varenyam Biolifesciences remains pre-revenue and will continue to incur losses during construction
p. 6
“VBPL or Varenyam Bio is pre-revenue and we will continue to absorb modest losses through the construction phase.”
Bhahim Desai, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.